Last $8.95 USD
Change Today -0.03 / -0.33%
Volume 5.3K
IRIX On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

iridex corp (IRIX) Snapshot

Open
$8.79
Previous Close
$8.98
Day High
$8.98
Day Low
$8.66
52 Week High
01/22/14 - $11.00
52 Week Low
04/26/13 - $4.67
Market Cap
89.4M
Average Volume 10 Days
17.0K
EPS TTM
$0.22
Shares Outstanding
10.0M
EX-Date
--
P/E TM
40.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for IRIDEX CORP (IRIX)

Related News

No related news articles were found.

iridex corp (IRIX) Related Businessweek News

No Related Businessweek News Found

iridex corp (IRIX) Details

IRIDEX Corporation develops, manufactures, markets, sells, and services medical laser systems and associated instrumentation for the treatment of the sight-threatening eye diseases worldwide. Its ophthalmology products consist of laser consoles, such as visible (yellow) photocoagulator console, infrared photocoagulator consoles, micropulse enabled consoles, and multi-wavelength laser system configurations. The company also provides ophthalmic delivery devices and other products, such as TxCell scanning laser delivery systems; TruFocus laser indirect ophthalmoscopes; slit lamp adapters; and operating microscope adapters. In addition, it offers EndoProbe, a fiber optic delivery device used for endophotocoagulation, a retinal treatment procedure; G-Probe, a sterile consumable multi-use product used in procedures to treat medically and surgically uncontrolled glaucoma; and DioPexy Probe, a hand-held instrument used in procedures to treat retinal tears. Further, the company provides GreenTip Soft Tip Cannula, a sterile disposable product, which allows surgeons to visualize and access the proximity of the retina while performing a fluid air exchange during a vitrectomy procedure; and MoistAir in-line air humidifier that provides humidified air to the eye during fluid air exchange. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It sells and markets its products through a direct sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.

101 Employees
Last Reported Date: 03/27/14
Founded in 1989

iridex corp (IRIX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $42.3K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $291.9K
Vice President of Operations
Total Annual Compensation: $138.5K
Compensation as of Fiscal Year 2012.

iridex corp (IRIX) Key Developments

IRIDEX Corporation Reports Unaudited Financial Results for the Fourth Quarter and Year Ended December 28, 2013; Provides Earnings Guidance for the First Quarter of 2014

IRIDEX Corporation reported unaudited financial results for the fourth quarter and year ended December 28, 2013. Revenues were $10.6 million in the fourth quarter of 2013, up 15% from $9.2 million in the prior year comparable period and up sequentially from $9.5 million in the third quarter of 2013. Operating income was $0.6 million compared with an operating income of $0.3 million for the fourth quarter of 2012. Net income from continuing operations was $0.4 million, or $0.04 per diluted share, for the fourth quarter of 2013, compared to a net income from continuing operations of $0.3 million, or $0.03 per diluted share, in the fourth quarter of 2012. Income from continuing operations before provision for income taxes was $385,000, compared to $287,000 for the last year. Net income was $412,000 or $0.04 per diluted share, compared to $242,000 or $0.02 per diluted share for the last year. Revenues for 2013 were $38.3 million, up 13% from $33.9 million in 2012. Operating income for 2013 was $2.6 million, up $3.5 million from an operating loss of $0.9 million in 2012. Net income from continuing operations for 2013 was $2.2 million compared to a loss from continuing operations of $0.2 million for 2012, or earnings of $0.22 per diluted share compared to a loss of $0.02 per share on a diluted basis. Income from continuing operations before provision for income taxes was $2,262,000, compared to loss of $270,000 for the last year. Net income was $2,231,000 or $0.22 per diluted share, compared to $1,438,000 or $0.16 per diluted share for the last year. For first quarter of 2014, the company expects to achieve revenue between $9.8 million and $10.1 million, representing growth of between 9% and 13% over the prior year period. Gross margin is anticipated to come in between 48% and 50%, operating expenses between $4.3 million and $4.5 million, and the company anticipates generating operating income.

IRIDEX Corporation, Q4 2013 Earnings Call, Feb 27, 2014

IRIDEX Corporation, Q4 2013 Earnings Call, Feb 27, 2014

IRIDEX Corporation to Report Q4, 2013 Results on Feb 27, 2014

IRIDEX Corporation announced that they will report Q4, 2013 results at 5:00 PM, Eastern Standard Time on Feb 27, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IRIX:US $8.95 USD -0.03

IRIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Anika Therapeutics Inc $40.86 USD -0.05
Cutera Inc $10.51 USD +0.09
Ellex Medical Lasers Ltd A$0.34 AUD 0.00
Lutronic Corp 16,850 KRW +100.00
Synergetics USA Inc $3.40 USD 0.00
View Industry Companies
 

Industry Analysis

IRIX

Industry Average

Valuation IRIX Industry Range
Price/Earnings 40.7x
Price/Sales 2.3x
Price/Book 3.4x
Price/Cash Flow 40.2x
TEV/Sales 2.0x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IRIDEX CORP, please visit www.iridex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.